Genmab A (GMAB) EPS (Weighted Average and Diluted) (2018 - 2026)

Genmab A has reported EPS (Weighted Average and Diluted) for 6 years, with the latest figure at $89.2 million in Q1 2026.

• For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 461.61% year-over-year to $89.2 million; the trailing twelve-month figure through Mar 2026 stood at $89.2 million (up 461.61% YoY), and the FY2025 full-year result was $15.37, down 12.32% from the prior year.
• EPS (Weighted Average and Diluted) for Q1 2026 stood at $89.2 million, up from $32.3 million in the prior quarter.
• The five-year high for EPS (Weighted Average and Diluted) was $89.2 million in Q1 2026, with the low at $14.1 million in Q1 2024.
• Historically, EPS (Weighted Average and Diluted) has averaged $35.9 million across 3 years, with a median of $28.1 million in 2024.
• Annual changes were most pronounced in 2025 — EPS (Weighted Average and Diluted) gained 12.27% — and 2026, when it soared 461.61%.
• Genmab A's EPS (Weighted Average and Diluted) stood at $28.1 million in 2024, then increased by 14.95% to $32.3 million in 2025, then jumped by 175.61% to $89.2 million in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $89.2 million (Q1 2026), $32.3 million (Q3 2025), and $15.9 million (Q1 2025), per Business Quant data.